Fate Therapeutics

About:

Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.

Website: http://www.fatetherapeutics.com

Twitter/X: fatethx

Top Investors: OrbiMed, ARCH Venture Partners, Venrock, Polaris Partners, Deep Track Capital

Description:

Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health. The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.

Total Funding Amount:

$1.34B

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

La Jolla, California, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)fatetherapeutics.com

Founders:

Alex Rives, David Scadden, Leonard Zon, Michael Rudnicki, Phillip Beachy, Randall Moon, Rudolf Jaenisch, Sheng Ding

Number of Employees:

501-1000

Last Funding Date:

2024-03-19

IPO Status:

Public

© 2025 bioDAO.ai